GSK: to present progress in hepatology

(CercleFinance.com) - GSK announces that it will present 12 abstracts at the 'Liver Meeting 2024' of the American Association for the Study of Liver Diseases, to be held 15-19 November in San Diego (US).


Presentations will focus on two investigational drugs, bepirovirsen (for chronic hepatitis B) and linerixibat (for cholestatic pruritus in primary biliary cholangitis).

Data on the HSD17B13 genetic target for steatotic liver disease will also be presented.

Chris Corsico, SVP in charge of development at GSK, commented that these abstracts demonstrate GSK's commitment to addressing unmet needs in severe liver disease.


Copyright (c) 2024 CercleFinance.com. All rights reserved.